Trans oral robotic surgery for oropharyngeal cancer: A multi institutional experience.

Humans Retrospective Studies Robotic Surgical Procedures / adverse effects Neoplasm Recurrence, Local / etiology Oropharyngeal Neoplasms / surgery Squamous Cell Carcinoma of Head and Neck Head and Neck Neoplasms
Cancer Chemotherapy Oropharyngeal Outcomes Quality of life Radiotherapy Survival Trans oral robotic surgery

Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
09 2023
Historique:
received: 11 01 2023
revised: 23 05 2023
accepted: 30 05 2023
medline: 13 9 2023
pubmed: 19 6 2023
entrez: 18 6 2023
Statut: ppublish

Résumé

Trans Oral Robotic Surgery (TORS) has proved to be a safe and feasible treatment for oropharyngeal squamous cell carcinoma (OPSCC). The aim of this study is to analyse oncological outcomes of OPSCC patients treated with TORS. This study involved 139 patients with OPSCC, treated with TORS between 2008 and 2020. Clinicopathological characteristics, treatment details and oncological outcomes were evaluated retrospectively. The management strategies included TORS alone in 42.5%, TORS-RT in 25.2% and TORS-CRT in 30.9%. The ENE was noted in 28.8% of neck dissections. In 19 patients clinically classified as unknown primaries, the primary was found in 73.7%. Rates of local, regional relapses and distant metastasis were 8.6%, 7.2%, and 6.5%, respectively. The 5 year- Overall Survival and Disease Free Survival were 69.6% and 71.3%, respectively. TORS fits well in the modern management of OPSCC. Although definitive CRT remains a milestone, TORS is proving to be a valid and safe treatment option. The choice of the therapeutic strategy requires evaluation by a multidisciplinary team.

Identifiants

DOI: 10.1016/j.ejso.2023.05.020 PMID: 37331862
pubmed: 37331862
pii: S0748-7983(23)00515-2
doi: 10.1016/j.ejso.2023.05.020
pii:
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106945

Informations de copyright

Copyright © 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Claudio Vicini is consultant and proctor for Intuitive Surgical Inc. Giuseppe Meccariello has nothing to declare. Manlio Gessaroli has nothing to declare. Raul Pellini has nothing to declare. Andrea De Vito has nothing to declare. Rossella Sgarzani has nothing to declare. Armando De Virgilio has nothing to declare. Andrea Costantino has nothing to declare. Flaminia Campo has nothing to declare. Giovanni Cammaroto has nothing to declare. Gerardo Petruzzi has nothing to declare. Bianca Festa has nothing to declare. Claudio Moretti has nothing to declare. Giuseppe Mercante has nothing to declare. Barbara Pichi has nothing to declare. Giuseppe Spriano has nothing to declare.

Auteurs

Armando De Virgilio (A)

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4, 20090, Pieve Emanuele, MI, Italy; Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, MI, Italy.

Raul Pellini (R)

Department of Otolaryngology-Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: raul.pellini@ifo.it.

Giovanni Cammaroto (G)

Otolaryngology and Head-Neck Surgery Unit, Department of Surgery, Morgagni Pierantoni Hospital, Azienda USL della Romagna, Forlì, Italy.

Rossella Sgarzani (R)

Plastic Surgery, DIMES Department, University of Bologna, Bologna, Italy.

Andrea De Vito (A)

Otolaryngology and Head-Neck Surgery Unit, Department of Surgery, Morgagni Pierantoni Hospital, Azienda USL della Romagna, Forlì, Italy.

Manlio Gessaroli (M)

Maxillo-Facial Unit, Department of Surgery, Maurizio Bufalini Hospital, Azienda USL della Romagna, Cesena, Italy.

Andrea Costantino (A)

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4, 20090, Pieve Emanuele, MI, Italy; Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, MI, Italy.

Gerardo Petruzzi (G)

Department of Otolaryngology-Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Bianca Maria Festa (BM)

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4, 20090, Pieve Emanuele, MI, Italy; Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, MI, Italy.

Flaminia Campo (F)

Department of Otolaryngology-Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Claudio Moretti (C)

Department of Otolaryngology-Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy; University of Ferrara, Ferrara, Italy.

Barbara Pichi (B)

Department of Otolaryngology-Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Giuseppe Mercante (G)

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4, 20090, Pieve Emanuele, MI, Italy; Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, MI, Italy.

Giuseppe Spriano (G)

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4, 20090, Pieve Emanuele, MI, Italy; Otorhinolaryngology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, MI, Italy.

Claudio Vicini (C)

Otolaryngology and Head-Neck Surgery Unit, Department of Surgery, Morgagni Pierantoni Hospital, Azienda USL della Romagna, Forlì, Italy; University of Ferrara, Ferrara, Italy.

Giuseppe Meccariello (G)

Otolaryngology and Head-Neck Surgery Unit, Department of Surgery, Morgagni Pierantoni Hospital, Azienda USL della Romagna, Forlì, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Trans oral robotic surgery for oropharyngeal...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Trans oral robotic surgery for oropharyngeal...
questionsmedicales.fr › Technologie, industrie et agriculture › Technologie › Automatisation › Interventions chirurgicales robotisées › Trans oral robotic surgery for oropharyngeal...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Trans oral robotic surgery for oropharyngeal...
questionsmedicales.fr › Maladies oto-rhino-laryngologiques › Maladies du pharynx › Tumeurs du pharynx › Tumeurs de l'oropharynx › Trans oral robotic surgery for oropharyngeal...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Carcinome épidermoïde de la tête et du cou › Trans oral robotic surgery for oropharyngeal...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Trans oral robotic surgery for oropharyngeal...